Page 1

Contact us!

We are internationally recognized in the field of in vivo immunology, regulation of innate and adaptive immunity and pathogenesis of murine cytomegalovirus (MCMV). Custom monoclonal antibody and hybridoma development - over 100 unique antibodies are already available through our web page: • mAbs against the whole Varicella Zoster Virus proteome • mAbs against murine and human CMV proteins • mAbs against lymphocyte markers Expression of your protein of choice in bacterial and eukaryotic expression systems or as Fc-fusion proteins.

• Biomedical research and technology expertise database of the University of Rijeka • Find all the information about the latest technologies and discoveries. • Contact our scientists and collaborate on research projects in the field of proteomics, immunology, virology and other biomedical fields. URL:

Center for Proteomics

Faculty of Medicine, University of Rijeka Braće Branchetta 20 51 000 Rijeka Croatia T +385 (0)51 651 260 F +385 (0)51 651 261


Development of novel immunotherapeutic approaches to treat viral infections based on fusion proteins consisting of anti-viral mAbs and soluble ligands for different lymphocyte receptors CMVs as vectors in vaccine development. We have constructed, tested and published our work on several highly attenuated cytomegalovirus strains that induce a strong innate immune response. Transcriptomic approach to virus disease research. We were the first to analyze and publish transcriptomic map of MCMV and analysis of host response using next-gen sequencing approach. We are established experts in mouse model of congenital CMV disease which we use to understand the mechanism of CMV spread to the brain and to develop preventive and therapeutic measures to reduce pathological outcomes.

capri brochure-bijela_v2.indd 1




Contact information for relevant institutions from the EU fund management system in Croatia: Central Finance and Contracting Agency (CFCA) Ministry of Science, Education and Sports (MSES) Science and Innovation Investment Fund (SIIF)

Further information on EU funds:

European Union INVESTING IN FUTURE This project has been co-financed by the European Union, from the European Regional Development Fund.

Ministry of Regional Development and EU Funds

29.07.2014. 10:33:47


Since its establishment the Center has participated in more than thirty collaborative projects with prestigious research institutes, universities and biotech SMEs from SE Europe, EU and the USA. Read more:

We are seeking new partnerships with academic institutions interested in: • joint fundamental research, • development of research tools and reagents, • innovative diagnostic and therapeutic products. Contact us at

C O L L A B O R AT E W I T H U S ! With a track record of more than 100 scientific, technological and innovation-oriented projects implemented in the past 10 years, we belong to the most successful academic institutions in Croatia in terms of funding from competitive programmes. Our projects are both nationally- and internationally-funded, including those granted by the European Commission’s 6th and 7th Framework Programmes and US National Institutes of Health.

We host the first Croatian European Research Council (ERC) Advanced Grant, the most prestigious grant for excellent researchers in the European Union. We are the only institution in Croatia with a principal investigator that was awarded a US National Institutes of Health grant. We have an experienced project management team, which, together with the researchers involved, currently has a grant applications success rate greater than 40%.

capri brochure-bijela_v2.indd 2

Our resources State-of-the-art antibody (mAb) facility.

monoclonal production

State-of-the-art SPF animal facility, one of the largest in this part of Europe, hosting 90 mouse strains and 12,000 mice. A multitude of MCMV and HCMV deletion mutants that are routinely employed in search for new viral evasive strategies. Expertise in multi-color flow cytometry and cell sorting. We are equipped with FACSAria cell sorter and FACSVerse analyzer.

INDU S T RY CO LLA B O RAT I ON What we are looking for: • Business partners with research activities in the field of proteomics and vaccine vector development.

Our ongoing with industry:


• Development of innovative technologies for highthroughput analysis of glycosylation of individual proteins to understand some key processes in immunity and infections • Production and characterization of various monoclonal antibodies against several protein antigens in the field of cardiovascular diseases

What makes us a valuable partner? • We are the unique department in Croatian academia – funded exclusively from competitive grants and commercial activities • We have a unique collection of validated antibodies available for non-exclusive licensing at • We have Technology Transfer Office (TTO Ri) with experts facilitating knowledge and technology transfer • We are interested in joint development of products with high technology readiness level and commercialization potential

• Production and characterization of novel human antibodies for the treatment of Type I Diabetes • Identification of trophoblasts in placenta issue and in human fluids using our antibodies to pregnancy-specific glycoproteins The content of this publication is the sole responsibility of the University of Rijeka Faculty of Medicine. Text: Ani Gerbin, Vanda Juranić Lisnić, Marta Begonja, Ivana Furčić Design: Vanda Juranić Lisnić

29.07.2014. 10:33:52

CAPRI brochure  
CAPRI brochure